| Objective:To explore whetherthe Fuzheng Huayu capsule combined with Entecavir is effective in improving liver stiffness and GP value in patients with compensated chronic hepatitis B-related cirrhosis and to verify the role of this therapy in anti-fibrosis,then to further optimize the treatment of anti-fibrosis.Methods:According to the research criteria,60 cases of hepatitis B cirrhosis compensated patients were enrolled fromJanuary 2016 to March 2017 in the Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine.The Fibrotouch and related laboratory examinations wereconsummated.Next,the above 60 cases of hepatitis B cirrhosis compensated patients were randomly divided into treatment group(30 cases)and control group(30 cases).The treatment group consisted of 23 males and 7 females,with an average age of 44.50 + 10.37 years.In the control group,there were 25 males and 5 females,with an average age of 41.80±10.29 years.Patients in the control group were treated with Entecavir capsule monotherapy,and patients in the treatment group were treated with Entecavir combined with Fuzheng Huayu Capsule.The patients in two groups were treated for 48 weeks.Before and after the clinical research,the liver stiffness,biochemical indicators,and safety indicators etc.of patients were observed and recorded.After the completion of clinical research,the collected data were statistically analyzed,comparing the difference between the two groups.Results:(1)The liver function index ALT,AST and TBIL of the two groups were improved in different degrees after treatment,and the difference was statistical significant(P<0.05).At twenty-fourth,forty-eighth weeks,the treatment group had better effect on alanine aminotransferase(ALT)and aspartate aminotransferase(AST)than the control group(P<0.05).Compared with the control group,the treatment group did not show a significant advantage in improving the total bilirubin(TBIL)in patients with compensated chronic hepatitis B-related cirrhosis,and the difference was not statistical significant(P>0.05).(2)The LSM values of the two groups were lower than those before the treatment(0 weeks),and the difference was statistical significant(P <0.05).At 24 weeks of treatment,there was no significant difference between the treatment group and the control group(P>0.05).After 48 weeks of treatment,the treatment group was better than the control group in reducing LSM,the difference was statistical significant(P<0.05).(3)At twenty-fourth weeks of treatment,there was no significant difference in GPmodel between two groups and before treatment(0 weeks)(P>0.05).At forty-eighth weeks of treatment,the GP model of the two groups decreased significantly compared with 0 weeks and 24 weeks,and the difference was statistical significant(P<0.05).There was no significant difference between the treatment group and the control group in improving the GP model of the patients(P>0.05).(4)At twenty-fourth weeks,the treatment group and the control group could significantly reduce the level of hyaluronic acid(HA).There was no significant difference in hyaluronic acid between the two groups(P>0.05).After forty-eighth weeks of treatment,hyaluronic acid levels in the two groups compared to 0 weeks and 24 weeks were significantly decreased,the difference was statistical significant(P<0.05).The patients in the treatment group decreased hyaluronic acid(HA)was better than the control group,the difference was statistical significant(P<0.05);After twenty-fourth weeks of treatment,both of two groups were significantly reduced laminin in patients,patients in the treatment group decreased laminin was better than the control group(P<0.05).After forty-eighth weeks of treatment,two groups of laminin levels were significantly decreased compared with 0 weeks(P<0.05),buttherewere no significant difference compared with the twenty-fourth week(P>0.05),patients in the treatment group decreased laminin was better than the control group(P<0.05);After twenty-fourth,forty-eighth weeks of treatment,the treatment group and the control group decreased significantly patients with type III procollagen(PC-III)(P<0.05),in the treatment group decreased in patients with type III procollagen were better than the control group(P<0.05);After twenty-fourth,forty-eighth weeks of treatment,the treatment group and the control group could significantly decrease the collagen type IV(IV-C),the treatment group was superior to the control group in reducing the type IV collagen(IV-C)(P<0.05).(5)At twenty-fourth,forty-eighth weeks of treatment,there was no significant difference in the number of complete virological responses between the treatment group and the control group(P>0.05).There was no significant difference between the treatment group and the control group in promoting the complete virological response of HBV-DNA(P>0.05).(6)The overall efficacy analysis,24 weeks of treatment,there was no significant difference between the treatment group and the control group(P>0.05);after 48 weeks of treatment,there wasstatistical significant differences between the treatment group and the control group(P<0.05),the treatment group on the therapeutic effect of anti-fibrosis in patients with hepatitis B liver cirrhosis is better than that of control group(P<0.05).Conclusions:BothEntecavir combined with Fuzheng Huayu capsule and Entecavir monotherapy can effectively improve the LSM value of HBV DNA positive patients during the 24 weeks treatment.After 48 weeks of treatment,Entecavir combined with Fuzheng Huayu capsule was superior to Entecavir monotherapy in improving the patient’s LSM.After 48 weeks of treatment,the two treatments could effectively reduce the GP value of the patients,but there was no significant difference between the two treatments.Entecavir combined with Fuzheng Huayu capsule has shown outstanding efficacy and safety in improving liver function,liver fibrosis and effective treatment.It has proved that the combination of Entecavir and traditional Chinese medicine plays a positive and important role in the field of anti-fibrosis. |
PDF Full Text Request